Novavax shot 96% effective against COVID-19 in trial

Novavax shot 96% effective against COVID-19 in trial

More On:

COVID vaccine

1 in 5 Americans say they lost a loved one to COVID-19, poll finds

Dating app now lets singles declare vaccination status

Singles are looking to score more than a shot on COVID vaccine lines

Moderna runs trials on new booster shots against COVID-19 variants

The COVID-19 vaccine from Novavax was found to be 96 percent effective against the original strain of the coronavirus in new a UK trial, the company announced Thursday.

The shot from the Maryland-based company was also 86 percent effective against the more contagious variant first discovered in the UK and now spreading across the US and in New York City.

In a smaller South Africa trial, the Novavax vaccine was only around 55 percent effective in preventing disease when tested against volunteers primarily exposed to the new variant first identified there.

But in both the UK and South Africa trials, the shot was 100 percent effective in preventing serious illness and death.

The company will use the findings to seek authorization for the vaccine’s use in various countries. It was not immediately clear if it will seek FDA authorization based on the UK findings, or if it will wait for the completion of an ongoing US test.

The latest findings are in line with interim results announced in January, when the Novavax jab was also found to be 96 percent effective against the original coronavirus and around 86 percent effective against the UK variant.

Currently, there are three vaccines authorized for use in the U.S., from Pfizer-BioNTech, Moderna and Johnson & Johnson.

With Post wires

Share this article:

Source: Read Full Article